256 related articles for article (PubMed ID: 26381823)
1. A role for the transducer of the Hippo pathway, TAZ, in the development of aggressive types of endometrial cancer.
Romero-Pérez L; Garcia-Sanz P; Mota A; Leskelä S; Hergueta-Redondo M; Díaz-Martín J; López-García MA; Castilla MA; Martínez-Ramírez A; Soslow RA; Matias-Guiu X; Moreno-Bueno G; Palacios J
Mod Pathol; 2015 Nov; 28(11):1492-503. PubMed ID: 26381823
[TBL] [Abstract][Full Text] [Related]
2. Hippo transducer TAZ promotes epithelial mesenchymal transition and supports pancreatic cancer progression.
Xie D; Cui J; Xia T; Jia Z; Wang L; Wei W; Zhu A; Gao Y; Xie K; Quan M
Oncotarget; 2015 Nov; 6(34):35949-63. PubMed ID: 26416426
[TBL] [Abstract][Full Text] [Related]
3. The Hippo Signaling Transducer TAZ Regulates Mammary Gland Morphogenesis and Carcinogen-induced Mammary Tumorigenesis.
Denson KE; Mussell AL; Shen H; Truskinovsky A; Yang N; Parashurama N; Chen Y; Frangou C; Yang F; Zhang J
Sci Rep; 2018 Apr; 8(1):6449. PubMed ID: 29691438
[TBL] [Abstract][Full Text] [Related]
4. The Hippo transducer TAZ promotes epithelial to mesenchymal transition and cancer stem cell maintenance in oral cancer.
Li Z; Wang Y; Zhu Y; Yuan C; Wang D; Zhang W; Qi B; Qiu J; Song X; Ye J; Wu H; Jiang H; Liu L; Zhang Y; Song LN; Yang J; Cheng J
Mol Oncol; 2015 Jun; 9(6):1091-105. PubMed ID: 25704916
[TBL] [Abstract][Full Text] [Related]
5. Fibulin-4 is associated with prognosis of endometrial cancer patients and inhibits cancer cell invasion and metastasis via Wnt/β-catenin signaling pathway.
Wang T; Wang M; Fang S; Wang Q; Fang R; Chen J
Oncotarget; 2017 Mar; 8(12):18991-19012. PubMed ID: 28177909
[TBL] [Abstract][Full Text] [Related]
6. Cysteine S-Glutathionylation Promotes Stability and Activation of the Hippo Downstream Effector Transcriptional Co-activator with PDZ-binding Motif (TAZ).
Gandhirajan RK; Jain M; Walla B; Johnsen M; Bartram MP; Huynh Anh M; Rinschen MM; Benzing T; Schermer B
J Biol Chem; 2016 May; 291(22):11596-607. PubMed ID: 27048650
[TBL] [Abstract][Full Text] [Related]
7. YAP/TAZ-Mediated Upregulation of GAB2 Leads to Increased Sensitivity to Growth Factor-Induced Activation of the PI3K Pathway.
Wang C; Gu C; Jeong KJ; Zhang D; Guo W; Lu Y; Ju Z; Panupinthu N; Yang JY; Gagea MM; Ng PK; Zhang F; Mills GB
Cancer Res; 2017 Apr; 77(7):1637-1648. PubMed ID: 28202507
[TBL] [Abstract][Full Text] [Related]
8. The Hippo effector TAZ (WWTR1) transforms myoblasts and TAZ abundance is associated with reduced survival in embryonal rhabdomyosarcoma.
Mohamed A; Sun C; De Mello V; Selfe J; Missiaglia E; Shipley J; Murray GI; Zammit PS; Wackerhage H
J Pathol; 2016 Sep; 240(1):3-14. PubMed ID: 27184927
[TBL] [Abstract][Full Text] [Related]
9. Recurrent WWTR1 S89W mutations and Hippo pathway deregulation in clear cell carcinomas of the cervix.
Kim SH; Basili T; Dopeso H; Da Cruz Paula A; Bi R; Issa Bhaloo S; Pareja F; Li Q; da Silva EM; Zhu Y; Hoang T; Selenica P; Murali R; Chan E; Wu M; Derakhshan F; Maroldi A; Hanlon E; Ferreira CG; Lapa E Silva JR; Abu-Rustum NR; Zamarin D; Chandarlapaty S; Matrai C; Yoon JY; Reis-Filho JS; Park KJ; Weigelt B
J Pathol; 2022 Aug; 257(5):635-649. PubMed ID: 35411948
[TBL] [Abstract][Full Text] [Related]
10. The Hippo Pathway as Drug Targets in Cancer Therapy and Regenerative Medicine.
Nagashima S; Bao Y; Hata Y
Curr Drug Targets; 2017; 18(4):447-454. PubMed ID: 26758663
[TBL] [Abstract][Full Text] [Related]
11. Nuclear TAZ expression associates with the triple-negative phenotype in breast cancer.
Díaz-Martín J; López-García MÁ; Romero-Pérez L; Atienza-Amores MR; Pecero ML; Castilla MÁ; Biscuola M; Santón A; Palacios J
Endocr Relat Cancer; 2015 Jun; 22(3):443-54. PubMed ID: 25870251
[TBL] [Abstract][Full Text] [Related]
12. ZEB1 overexpression associated with E-cadherin and microRNA-200 downregulation is characteristic of undifferentiated endometrial carcinoma.
Romero-Pérez L; López-García MÁ; Díaz-Martín J; Biscuola M; Castilla MÁ; Tafe LJ; Garg K; Oliva E; Matias-Guiu X; Soslow RA; Palacios J
Mod Pathol; 2013 Nov; 26(11):1514-24. PubMed ID: 23743934
[TBL] [Abstract][Full Text] [Related]
13. CSE1L promotes nuclear accumulation of transcriptional coactivator TAZ and enhances invasiveness of human cancer cells.
Nagashima S; Maruyama J; Honda K; Kondoh Y; Osada H; Nawa M; Nakahama KI; Ishigami-Yuasa M; Kagechika H; Sugimura H; Iwasa H; Arimoto-Matsuzaki K; Nishina H; Hata Y
J Biol Chem; 2021 Jul; 297(1):100803. PubMed ID: 34022224
[TBL] [Abstract][Full Text] [Related]
14. The Hippo Pathway Effector TAZ Regulates Ferroptosis in Renal Cell Carcinoma.
Yang WH; Ding CC; Sun T; Rupprecht G; Lin CC; Hsu D; Chi JT
Cell Rep; 2019 Sep; 28(10):2501-2508.e4. PubMed ID: 31484063
[TBL] [Abstract][Full Text] [Related]
15. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.
Janse van Rensburg HJ; Azad T; Ling M; Hao Y; Snetsinger B; Khanal P; Minassian LM; Graham CH; Rauh MJ; Yang X
Cancer Res; 2018 Mar; 78(6):1457-1470. PubMed ID: 29339539
[TBL] [Abstract][Full Text] [Related]
16. TAZ
Yao CB; Zhang M; Zhou X; Lei QY; Yin M
Biochem Biophys Res Commun; 2018 Sep; 503(4):2240-2247. PubMed ID: 29953851
[TBL] [Abstract][Full Text] [Related]
17. SKI activates the Hippo pathway via LIMD1 to inhibit cardiac fibroblast activation.
Landry NM; Rattan SG; Filomeno KL; Meier TW; Meier SC; Foran SJ; Meier CF; Koleini N; Fandrich RR; Kardami E; Duhamel TA; Dixon IMC
Basic Res Cardiol; 2021 Apr; 116(1):25. PubMed ID: 33847835
[TBL] [Abstract][Full Text] [Related]
18. Eva-1 homolog A promotes papillary thyroid cancer progression and epithelial-mesenchymal transition via the Hippo signalling pathway.
Lin BY; Wen JL; Zheng C; Lin LZ; Chen CZ; Qu JM
J Cell Mol Med; 2020 Nov; 24(22):13070-13080. PubMed ID: 32969138
[TBL] [Abstract][Full Text] [Related]
19. Activation of the Hippo/TAZ pathway is required for menstrual stem cells to suppress myofibroblast and inhibit transforming growth factor β signaling in human endometrial stromal cells.
Zhu H; Pan Y; Jiang Y; Li J; Zhang Y; Zhang S
Hum Reprod; 2019 Apr; 34(4):635-645. PubMed ID: 30715393
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of MiR-31 stimulates expression of LATS2 via the hippo pathway and promotes epithelial-mesenchymal transition in esophageal squamous cell carcinoma.
Gao Y; Yi J; Zhang K; Bai F; Feng B; Wang R; Chu X; Chen L; Song H
J Exp Clin Cancer Res; 2017 Nov; 36(1):161. PubMed ID: 29145896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
